Fizazi et al., 2015 - Google Patents
Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancerFizazi et al., 2015
View PDF- Document ID
- 4543383604433083889
- Author
- Fizazi K
- Massard C
- Smith M
- Rader M
- Brown J
- Milecki P
- Shore N
- Oudard S
- Karsh L
- Carducci M
- Damião R
- Wang H
- Ying W
- Goessl C
- Publication year
- Publication venue
- European urology
External Links
Snippet
Background Previous studies have reported on prognostic factors for castration-resistant prostate cancer (CRPC); however, most of these studies were conducted before docetaxel chemotherapy was approved for CRPC. Objective To evaluate the prognostic value of …
- 230000004083 survival 0 title abstract description 71
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
- G06F19/345—Medical expert systems, neural networks or other automated diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce, e.g. shopping or e-commerce
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fizazi et al. | Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer | |
| Lakshman et al. | Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria | |
| Allison et al. | Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update | |
| Schweizer et al. | Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy | |
| Shappley III et al. | Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort | |
| Wymer et al. | Adherence to National Comprehensive Cancer Network® guidelines for testicular cancer | |
| Oh et al. | Natural history of gastric cancer: observational study of gastric cancer patients not treated during follow-up | |
| Halabi et al. | Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy | |
| Turner et al. | Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma | |
| Halabi et al. | Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer | |
| Henry et al. | The joint effects of census tract poverty and geographic access on late-stage breast cancer diagnosis in 10 US States | |
| Lin et al. | Risk prediction and clinical model building for lymph node metastasis in papillary thyroid microcarcinoma | |
| Mir et al. | Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy | |
| Trinh et al. | In-hospital mortality and failure to rescue after cytoreductive nephrectomy | |
| Bittoni et al. | Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for medicare patients 65 years and older with advanced non–small-cell lung cancer: a retrospective study | |
| Grant et al. | Development and validation of a score to predict acute care use after initiation of systemic therapy for cancer | |
| Lin et al. | Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model | |
| Martí et al. | Prognostic value of serum neutrophil gelatinase‐associated lipocalin in metastatic and nonmetastatic colorectal cancer | |
| Murphy et al. | Impact of a genomic test on treatment decision in a predominantly African American population with favorable-risk prostate cancer: a randomized trial | |
| Hammerich et al. | Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer | |
| Samson et al. | Defining the ideal time interval between planned induction therapy and surgery for stage IIIA non-small cell lung cancer | |
| Valicenti et al. | Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92–02 | |
| Joranger et al. | Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach | |
| Bell et al. | Remaining lifetime after recognition of terminal illness depends on diagnosis: a nationwide population-based cohort study | |
| Michalopoulou et al. | Impact of comorbidities at diagnosis on the 10-year colorectal cancer net survival: A population-based study |